The main findings of this clinical study are that in patients with unstable angina, trimetazidine treatment prevented the increase in CK-MB, cTnI, and vWF and the decrease in NO induced by PCI but did not significantly affect the levels of h-FABP. Here, VWF is linked to angina pectoris.